Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 334 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Excipient Clear all
Completed Phase 3 Interventional Results available

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

NCT02224703
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P, Placebo Control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

NCT01039675
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
500mcg/25mcg once daily, Placebo once daily
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Chester, South Carolina • Gaffney, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

NCT01841281
View directory record Official record
Conditions
Asthma, Inflammation
Interventions
L-Arginine, Placebo
Drug
Lead sponsor
Nicholas Kenyon
Other
Eligibility
19 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 20, 2026, 1:50 PM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Not yet recruiting Not applicable Interventional

Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults

NCT07447843
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Redefine, Placebo
Dietary Supplement
Lead sponsor
Nature's Sunshine Products, Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lehi, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Recruiting Phase 2 Interventional

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

NCT07580716
View directory record Official record
Conditions
Primary Knee Osteoarthritis
Interventions
Allocetra, Placebo
Drug · Other
Lead sponsor
Enlivex Therapeutics Ltd.
Industry
Eligibility
64 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Longwood, Florida • Miami, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Not listed Phase 1Phase 2 Interventional

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

NCT01099332
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
Other
Lead sponsor
Adeona Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Clearwater, Florida • Holiday, Florida • Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

NCT04304144
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

NCT03787628
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol (CBD) 600 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tarzana, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Not applicable Interventional Results available

VITATOPS: A Study of VITAmins TO Prevent Stroke

NCT00097669
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo, Placebo
Drug · Other
Lead sponsor
VITATOPS
Government
Eligibility
Not listed
Enrollment
8,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
4
States / cities
New York, New York • Abington, Pennsylvania • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional Results available

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

NCT04925713
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
IFx-Hu2.0
Biological
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 1:50 PM EDT
Recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102, Vehicle
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Saint Augustine, Florida • Plainfield, Indiana • Hunt Valley, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers

NCT02717988
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SKI-O-703 capsule, Placebo capsule
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

NCT03815916
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects

NCT02222896
View directory record Official record
Conditions
Surgery
Interventions
Chlorhexidine Gluconate, Vehicle, DynaHex-2
Drug · Other
Lead sponsor
Medline Industries
Industry
Eligibility
16 Years and older
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

NCT01162785
View directory record Official record
Conditions
Bladder Cancer
Interventions
SCH 721015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 20, 2026, 1:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07427797
View directory record Official record
Conditions
Moderate to Severe Glabellar Lines
Interventions
Corabotase, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

NCT06813261
View directory record Official record
Conditions
Postmenopause, Metabolism, Geroscience
Interventions
GLYLO, Placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 20, 2026, 1:50 PM EDT